Seeking Alpha

Oxygen shares soar following positive Levosimendan data

  • Oxygen Biotherapeutics' (OXBT) Levosimendan product significantly improves post-operative kidney function in patients who have undergone surgery of the mitral valve in the heart, evidence from a study published in the Journal of Cardiothoracic & Vascular Anesthesia shows.
  • Oxygen Biotherapeutics expects to begin a Phase III trial of Levosimendan in Q3 for patients undergoing coronary artery by-pass and or mitral valve surgery.
  • Shares +22%. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: